Anticoagulation-related complications and their outcomes in hemodialysis patients with acute kidney injury at selected hospitals in Ethiopia ============================================================================================================================================ * Hanan Muzeyin Kedir * Abdella Birhan Yabeyu * Addisu Melkie Ejigu * Tamrat Assefa Tadesse * Eskinder Ayalew Sisay ## Abstract **Introduction** During hemodialysis (HD), the presence of clots in the dialyzer can diminish the effective surface area of the device. In severe cases, clot formation in the circuit can halt treatment and lead to blood loss in the system. Thus, ensuring proper anticoagulation during HD is crucial to prevent clotting in the circuit while safeguarding the patient from bleeding risks. This study aimed to evaluate anticoagulation outcomes and related factors in HD patients with acute kidney injury (AKI) at selected hospitals in Ethiopia. **Method** A prospective, multicenter observational study was carried out between October 1, 2021, and March 31, 2022. The study encompassed all AKI patients undergoing HD at least once during the study period. Descriptive statistics were utilized to summarize the data, and multinomial logistic regression analysis was employed to identify factors associated to clotting and bleeding. **Results** Data were gathered from 1010 HD procedures conducted on 175 patients. Extracorporeal circuit clotting was detected in 34 patients during 39 (3.9%) dialysis sessions, while bleeding incidents occurred in 27 patients across 29 (2.9%) sessions. A statistically significant association was found between both the total number of HD treatments and blood flow rate with incidents of clotting. Factors such as length of hospitalization, serum creatinine levels at admission, signs and symptoms associated with uremia, along with utilization of anticoagulants or antiplatelet medications demonstrated an association with bleeding events. **Conclusion** Clotting affected 19.4% of participants, while bleeding occurred in 15.4%, underscoring the importance of close monitoring. The frequency of HD sessions and blood flow rate are correlated with clotting, while hospitalization duration, serum creatinine levels, uremic symptoms, and anticoagulant use are associated with bleeding events. Keywords * Acute kidney injury * Anticoagulation * Hemodialysis * Ethiopia ## Introduction Hemodialysis (HD) constitutes a medical procedure that facilitates the removal of waste products from the bloodstream externally via a device outfitted with specialized filtration systems. The predominant cause for arteriovenous access failure is attributed to thrombosis, representing 80%-85% of cases (1,2). Within the HD protocol, components such as the dialyzer and other elements of the extracorporeal blood circuit are also vulnerable to thrombotic events. This includes tubing, arterial and venous bubble traps in addition to needles or catheters utilized for vascular access—all factors contributing to coagulation phenomena (3,4). Notably, arterial and venous bubble traps exhibit a heightened susceptibility towards clotting owing to diminished blood flow rates leading potentially to stasis and hence clot formation. Such premature cessation of HD sessions precipitates inadequate dialysis alongside possible hematologic losses. Furthermore clots within this circuitry can herald significant negative repercussions including reduction in solute clearance during therapy amplified costs, and increased operational burden (5–7). Maintaining an optimal balance between insufficient and excessive heparinization is essential for achieving proper anticoagulation during HD in order to avert bleeding and clot formation within the extracorporeal circuit, respectively (6, 8). It is imperative to administer the minimal efficacious dose of anticoagulant to ensure that the dialyzer and venous chamber remain clear of blood cell fragments while also facilitating rapid hemostasis at the vascular access site following treatment (5). Although anticoagulant dosing varies among individuals due to patient-specific factors and HD-related variables, it is generally lower than doses required for full anticoagulation. Inadequate levels of anticoagulation may reduce dialysis’s effectiveness in eliminating waste products from the bloodstream (4–6). Unfractionated heparin (UFH) is extensively utilized as an anticoagulant during HD owing to its long-standing history in clinical practice and a desirable safety profile characterized by a brief half-life (8,9). The European guidelines for optimal HD practices suggest an initial bolus of 50 IU/kg UFH administered via the arterial access needle, followed by a continuous infusion maintenance dosage ranging from 500 to 1500 IU of UFH per hour. It’s recommended that the use of UFH be minimized, especially since patients with acute kidney injury AKI often have compromised health and may require daily dialysis treatments. In instances of clotting or bleeding, modifications in dosage or the implementation of heparin-free dialysis methods might become necessary. Although alternative anticoagulation techniques targeting the extracorporeal circuit exist, their adoption has been limited due to their complex nature and higher requisites for administration time and workforce involvement for monitoring purposes (10–12). Critically ill patients often display impaired coagulation and low platelet counts, which significantly increases their risk of bleeding when systemic anticoagulants are used. As such, it is advised that these individuals avoid any treatments that further heighten this risk, especially those involving systemic anticoagulants (6,13). In situations where the risk of bleeding is a concern, the European Best Practice Guidelines recommend alternatives like regular saline flushing or local citrate anticoagulation during HD, avoiding systemic anticoagents entirely. This approach not only facilitates quick adjustments to treatment but also enables easy monitoring for clotting within the dialyzer and may help in preventing clots from forming initially (2,10). The goal of this study is to explore outcomes related to anticoagulation therapy and factors influencing its outcome among AKI patients receiving HD at Tikur Anbessa Specialized Hospital (TASH) and St. Paul’s Hospital Millennium Medical College (SPHMMC) in Addis Ababa, Ethiopia. ## Material and Methods ### Study Setting The study took place in the dialysis departments of TASH and SPHMMC, located in Addis Ababa, Ethiopia. TASH introduced HD services back in 1980 and presently caters to acute dialysis needs. Meanwhile, SPHMMC began its provision of acute dialysis services in August 2013 before extending these services to include maintenance dialysis for kidney transplantation starting from early 2015 (14). Despite the lack of a specific written protocol for HD patients, anticoagulation was frequently administered at both hospitals. UFH was used during HD, but the prescribed doses of heparin varied slightly between the two centers. At TASH, UFH was administered in one of three ways: (i) the standard dose, 1 ml (5000 IU) of UFH, was diluted with 4 ml of normal saline (total of 5 ml). This was followed by a 2 ml initial bolus and a continuous infusion of 1 ml/hr; (ii) the minimal or half dose of 0.5 ml (2500 IU) of UFH was diluted with 4.5 ml of normal saline (total of 5 ml). This was followed by a 2 ml initial bolus and a continuous infusion of 1 ml/hr; (iii) heparin-free saline flushes of 30 to 50 ml were given every 30 minutes. At SPHMMC, 1 ml of UFH was diluted with 3 ml of normal saline (total of 4 ml) and administered as a bolus of 1 ml, followed by a continuous infusion of 1 ml/hr. ### Study Design and Period A comprehensive, multicenter observational study was carried out over a duration of six months, starting from October 1st, 2021 and concluding on March 31st, 2022. This study took place at two major hospitals (TASH and SPHMMC) in Addis Ababa, Ethiopia. ### Sampling and Sample Size Determination On average, the dialysis clinics at TASH and SPHMMC serve approximately 15 and 30 AKI patients per month, respectively. All patients meeting the eligibility criteria were considered for inclusion in the study. Consequently, a total of 175 patients identified during the study period, meeting the established criteria, participated in this research. Specifically, 122 of these patients received treatment at SPHMMC, while the remaining 53 were from TASH. ### Inclusion and Exclusion Criteria All patients suffering from AKI, aged 12 years and older, who underwent HD at least once during the designated study period were eligible for inclusion in this study. Nonetheless, individuals diagnosed with chronic kidney disease who were undergoing regular maintenance dialysis treatments, as well as those who expressed a refusal to participate in the study, were systematically excluded from consideration. ### Data Collection Instruments and Techniques The data collection questionnaire, consisting of four sections, was developed through a thorough review of relevant literature related to the study’s objectives. The aim was to collect demographic characteristics and clinical variables of patients to assess outcomes related to anticoagulation. Pre-testing was carried out, and all necessary adjustments to the data collection tool were implemented(4,6,9,15–18). The initial section of the data collection tool was designed to gather information regarding the sociodemographic characteristics of the patients. Subsequently, the second section assessed the clinical features of the patients, including inquiries about the cause of AKI, indications for HD, concomitant medical conditions, co-administered medications, and current use of anticoagulants and/or antiplatelet drugs. The third part of the data collection tool focused on recording essential laboratory results upon admission and discharge. Finally, the fourth section specifically documents the comprehensive details of each HD session. Patients were closely monitored during each session, with data collectors prospectively recording various parameters related to HD, such as venous pressure, ultrafiltration volume, blood flow, dialysate flow, and approach to UFH usage during HD. Additionally, incidents of clotting or bleeding were documented, along with the interventions implemented to manage these occurrences. ### Data Quality Assurance To ensure data quality, the principal investigator closely monitored each activity to ensure comprehensive data collection. Unclear terms were promptly clarified, and the necessary corrections were made during the pre-test phase before commencing the main study. Data collection was performed using three BSc. nurses and a pharmacist who were recruited as data collectors. They underwent training to establish a consistent understanding and interpretation of the instrument, including a briefing on the study’s objectives and commitment to maintaining core ethical principles throughout the data collection period. ### Data Analysis Data completeness was verified before entering the statistical package for social science (SPSS) version 26 for a thorough analysis. Descriptive statistics, including the mean, median, percentage, and standard deviation (SD), were then used to succinctly summarize the data. Multinomial logistic regression was used to identify predictive factors for anticoagulation-related outcomes in patients with AKI undergoing HD. A P-value < 0.05 was considered the threshold for declaring statistically significant associations. ### Ethical Considerations Ethical clearance was secured from Addis Ababa University, School of Pharmacy, the Ethical Review Committee (reference number ERB/SOP/257/13/2021), and the Institutional Review Board of SPHMMC (reference number PM25/386). Study participants provided both written and verbal consent before participating, and their confidentiality was maintained by avoiding the recording of identifying information such as patient names. The collected data remained securely stored throughout the study and was appropriately destroyed upon study completion. ### Operational Definition Anticoagulation-related complication: were defined as the occurrence of any circuit clotting or bleeding during HD, whether with the use of UFH as an anticoagulant for dialysis or in a heparin-free approach. ## Results ### Socio-demographic Characteristics of Study Participants Of the 175 patients included in the study, an almost equal number were males (50.9%) and females (49.1%), with a mean age of 40 ± 17.8 years involved and four female were pregnant. Among the 175 patients, 66.9% were paid out-of-pocket for dialysis and 2.3% were involved in smoking, drinking alcohol, and chewing khat (Table 1). View this table: [Table 1:](http://medrxiv.org/content/early/2024/02/29/2024.02.28.24303493/T1) Table 1: Socio-demographic characteristics of AKI patients who undergo HD (n=175) ### Clinical Characteristics The average length of hospital stay was 14.2 days, range, 2–40 days. The three most common causes of AKI were acute tubular necrosis (29%), nephrotic syndrome (24%), and sepsis (22.9%). Pregnancy-related causes also included preeclampsia/eclampsia (5.1%) and HELLP syndrome (4.6%). The major indications for dialysis were uremic signs and symptoms (70.3%), followed by fluid overload (50.3%). Common underlying comorbidities identified were hypertension (55.4%) and anaemia (49.7%), and 13.1% of AKI cases were superimposed on chronic kidney disease. UFH 7500 IU twice per day (48%) was the most widely used anticoagulant regimen in the study population, followed by 5000 IU twice a day (14.3%) to prevent deep venous thrombosis (Table 2). View this table: [Table 2:](http://medrxiv.org/content/early/2024/02/29/2024.02.28.24303493/T2) Table 2: Clinical characteristics of AKI patients who undergo HD (n=175) ### Laboratory Findings Upon admission and upon discharge, it was noted that there were low hemoglobin levels present. Furthermore, the mean serum creatinine level recorded at the time of admission stood at 8.3 ± 3.4 mg/dl, which experienced a significant decrease by 3 mg/dl by the time of discharge. Table 3 in our document provides a summarized outline showing these changes among other selected laboratory parameter values observed during this period. View this table: [Table 3:](http://medrxiv.org/content/early/2024/02/29/2024.02.28.24303493/T3) Table 3: Selected Laboratory Values of AKI patients who undergo HD (n=175) View this table: [Table 4:](http://medrxiv.org/content/early/2024/02/29/2024.02.28.24303493/T4) Table 4: Characteristics of HD sessions included in the study (N=1010) ### Characteristics of HD Sessions From October 2021 to March 2022, a total of 1010 HD sessions were conducted on 175 patients. The average frequency of dialysis sessions was calculated at 5.8 ± 3.8 per patient, ranging from one single session to a maximum of fifteen sessions with each session lasting an average duration of approximately 3.1 ± 0.6 hours. Patients underwent HD therapy thrice weekly using catheters as the primary means for vascular access across all cases in this study. During these treatments, blood products were administered in approximately 9.8% or essentially, during almost ten out all hundred HD procedures. UFH was administered for circuit anticoagulation in 626 sessions, accounting for 62% of the total. The average dose given was 1 mL (5000 IU). Of these UFH sessions, infusion was stopped 60 minutes before discontinuation in 546 cases, making up 87.2% of the total. The average pressure in the venous chamber was recorded as 125 ± 39.3 mmHg, with the dialysis blood flow rate averaging 227.2 ± 22.8 ml/min. ### Anticoagulation-related complication and HD Outcome Of the 175 patients, extracorporeal circuit clotting occurred in 34 patients in 39 (3.9%) sessions and 27 patients in 29 (2.9%) experienced bleeding. HD circuit clotting resulted in the discarding of the bloodline and early termination of dialysis in 17 sessions. Additionally, nursing interventions, that is, the use of UFH and a normal saline flush, were required in 10 and 5 sessions, respectively, to prevent abrupt HD treatment interruptions due to circuit clotting. Some of the measures taken when bleeding occurred included holding UFH at the time, and for the next session/s (n = 14 sessions), blood transfusion (n = 2 sessions), and applying pressure at catheter insertion site in 6 sessions (Table 5). On the other hand, the majority of AKI patients (44.6%) were discharged with improvement, while more than one-fourth (26.9%) of them died after undergoing HD (Figure 1). ![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/02/29/2024.02.28.24303493/F1.medium.gif) [Figure 1:](http://medrxiv.org/content/early/2024/02/29/2024.02.28.24303493/F1) Figure 1: HD outcome among AKI patients in the study View this table: [Table 5:](http://medrxiv.org/content/early/2024/02/29/2024.02.28.24303493/T5) Table 5: Anticoagulation related complication and HD outcome among AKI patients in the study. ### Factors associated with anticoagulation related outcomes To determine the predictors of anticoagulation-related outcomes during HD (clotting and bleeding risks), multinomial regression analysis was used. Based on the model comparing participants who had HD circuit clotting with those who did not have any clotting/bleeding, as the total number of HD sessions increased, the probability of circuit clotting increased (AOR=1.932, 95% CI, 1.227-3.043, p= 0.004). In contrast, a higher blood flow rate was associated with a lower HD circuit clotting risk (AOR=0.868, 95% CI, 0.812-0.928, p= 0.001). On the other hand, bleeding was more likely to occur in participants who had longer hospitalization and elevated serum creatinine at admission (AOR=1.247, 95% CI, 1.053-1.478, p= 0.010; AOR=1.886, 95% CI, 1.285-2.769, p= 0.001) respectively. While, the rate of bleeding in patients who had no uremic signs and symptoms was lower (AOR=0.092, 95% CI, 0.009-0.955, p= 0.004) than those having it. Likewise, patients who did not receive prophylactic or therapeutic anticoagulant and/or antiplatelet drug were less likely to develop bleeding (AOR=0.017, 95% CI, 0.001-0.446, p= 0.014) compared to those taking these drugs (Table 6). View this table: [Table 6:](http://medrxiv.org/content/early/2024/02/29/2024.02.28.24303493/T6) Table 6: Multinomial regression of predictive factors associated with anticoagulation related outcomes during HD ## Discussion As the first prospective study in the Ethiopian context on anticoagulation among patients with AKI on HD, this study provides insight into extracorporeal circuit clotting or bleeding occurrences and the predictive factors associated with these complications. In this study, 1010 HD sessions performed on 175 patients were prospectively followed. Clotting and bleeding data are expressed as percentages of both participants and sessions. Circuit clotting occurred in 3.9% of HD sessions (19.4% patients), and bleeding in 2.9% sessions (15.4% patients). A similar result was reported in the United States of America, that evaluated clotting of the HD circuit in general care patients and critically ill patients. The overall rate of extracorporeal circuit clotting was 5.2% in all sessions (12). Circuit clotting occurred in 2.4% of HD sessions with heparin, according to a retrospective study comparing two intra-dialytic heparin protocols: “routine heparin-use” during HD (routine heparin prime/bolus dose) and heparin-free HD (saline prime, heparin avoidance). However, heparin-free HD is associated with a higher rate of HD circuit clotting (9.1%) (13). In contrast, other studies reported a higher rate of circuit clotting during HD. A study conducted in Brazil showed that filter clotting occurred in 19 patients (25.3%) and 29 sessions (14.9%) (19). This study evaluated and compared intra- and post-dialysis complications in critically ill AKI patients undergoing extended daily dialysis sessions of different durations (6 versus 10 hours), which could explain the higher rate of HD filter clotting events, and the fact that many critically ill patients develop hemostatic abnormalities in addition to the longer dialysis duration. Additionally, a retrospective cohort study conducted in Belgium found that circuit coagulation was reported in 17.5% of the sessions. This higher rate of clotting events could be attributed to the absence of systemic anticoagulation (20). Moreover, this study conducted a retrospective analysis of HD sessions in intensive care unit patients, which could be an additional factor contributing to clotting occurrences. Patients admitted to the intensive care unit and requiring dialysis for AKI often present with a systemic inflammatory state (21), which is known to be associated with the activation of coagulation pathways (22). Lower clotting of the HD circuit incidence was reported in a retrospective study conducted in the USA (1% of 400 HD treatments) (23). This may be attributed to the operational definition of clotting used in this study. The researchers defined clotting as complete clotting that required replacement of the blood tubing and dialyzer to complete treatment. The higher blood flow rate (378 ± 46 mL/min) and more aggressive normal saline flushing of the circuit employed in this protocol could also explain the lower rate of clotting. Moreover, there might be underreporting of clots due to the retrospective study design, in which existing data were extracted from chart reviews. Another study from Spain found that 1.9% of patients developed clotting, which is lower than our finding (19.4% of patients) with a higher mean blood pump flow (346 ± 47 ml/min), given a higher risk of coagulation from a lower pump flow (17). In the current study, 15.4 % of patients developed bleeding, and this finding was higher than a study conducted in Spain (4.4%) (17). This variation might be due to the difference in the study design and setting, even though the study reported that oral anticoagulants were administered to 18.4% of patients, which by itself is thought to increase the risk of bleeding. However, in a Spanish study, each patient was asked to report any bleeding or thrombotic complications that arose in the week prior to data collection. In the present study, it was observed that anticoagulation was achieved with UFH or saline flushes of 30 to 50 ml administered every 30 min if UFH was contraindicated. There were three strategies regarding UFH order for HD in current study settings, and each patient was dialyzed using any of these anticoagulation methods. The first is the standard dosing regimen of UFH, consisting of a bolus of 1250–2000 U, followed by a continuous infusion of 1000–1250 U/h. The second was the minimal/half-dose method with a 625–1000 bolus dose and 500–625 infusion rate. Heparin-free dialysis was also the third method used in patients who were actively bleeding or were at an increased risk of bleeding. Due to its brief half-life and extensive medical usage over time, UFH has emerged as the predominant anticoagulant for HD (9). Nonetheless, the dosage administered shows significant divergence. This study reveals that the average total UFH dose throughout HD sessions was 5000 ± 1000 units, with heparin infusion being discontinued one hour before dialysis completion in the majority (87.2%) of cases to reduce the potential for bleeding from the access site post needle withdrawal. In the present study, extracorporeal circuit clotting was assessed by visual inspection and noted by nurses. It is characterized by extremely dark blood or black striations in the tube and a sudden rise in pressure readings. They only recorded clotting as being present or absent without grading it in line with several studies done elsewhere (13,17,19,24). In contrast, other studies have reported the degree of clotting by classifying it as mild/slight, moderate, and severe. HD is often performed three times a week for three–four hours each session; however, the length of these sessions varies from patient to patient. One consequence of intradialysis, circuit clotting, includes treatment interruption and patient blood loss, which may exacerbate haemodynamic instability (19). In 1.7% of all sessions with clotting, dialysis was stopped early without the possibility of retransfusing blood from the extracorporeal circuit; hence, the bloodline was discarded. However, in 0.2% of the sessions, dialysis was terminated early by the return of blood. According to a study from Belgium, clotting reduced the length of time spent receiving dialysis in 15.2% of sessions, completely blocking the circuit, and preventing retransfusion in 4.2% of sessions, which is greater than our findings (20). These variations may be due to differences in dialysis protocols. In contrast to our study, the study combined a citrate-enriched dialysate with a heparin-coated dialyzer with no systemic UFH. Similarly, a study conducted in the USA comparing two intradialytic heparin protocols reported that in a heparin-free HD protocol, circuit clotting resulted in a change of the extracorporeal circuit in 7.3% of sessions. However, this was required in only 0.8% of HD sessions with heparin, and early termination of HD (1.6%) was similar to that in this study (13). Bleeding is another important intradialysis complication that might require adjusting the dose of UFH (1.6% of all sessions with bleeding) or blood transfusion (0.2%). Another study revealed that patient weight, circuit clotting, and bleeding of the vascular access after disconnection were the most frequently employed techniques for changing the dosage (17). Identifying predictors of anticoagulation-related outcomes during HD in patients with AKI is important. Identifying and preventing patients at risk of such complications can increase practitioner awareness of HD-related complications. Similar to other studies (12,13,20,23), the blood flow rate showed a statistically significant association with the occurrence of circuit clotting. In this study, lower delivered blood flow rates were associated with higher circuit-clotting rates. Additionally, as the total number of HD sessions increased, the probability of circuit clotting increased, unlike in a study conducted in Belgium (20). This difference could be due to variations in their research methodology and the inclusion of study participants with varying levels of clotting risk. Patients who did not receive prophylactic or therapeutic anticoagulants and/or antiplatelet drugs were less likely to develop bleeding compared to those taking these drugs. Similarly, a study from Spain found that bleeding complications were more frequent in patients receiving oral anticoagulants (17). Consistent with previous studies, age and sex were not associated with bleeding events (13,17). However, there were some limitations to our study. Bleeding was reported only at the time of the dialysis session. Therefore, this may not provide a comprehensive picture of the bleeding risk associated with dialysis. Additionally, the study did not exclude patients with comorbidities (such as deep vein thrombosis, active malignancy, severe heart failure, or severe liver disease). These conditions can impact anticoagulation outcomes and may confound the interpretation of results. ## Conclusions In conclusion, clotting was observed in 19.4% of the participants in the study, while bleeding was reported in 15.4% of them. These findings highlight the importance of thorough monitoring due to the complications resulting in treatment interruptions and blood loss. The study identified a significant association between circuit clotting and variables such as blood flow rate and the frequency of HD sessions. Furthermore, it revealed a notable occurrence of bleeding during HD, mainly manifesting as minor cases. Individuals who received prophylactic or therapeutic anticoagulants and/or antiplatelet medications were more susceptible to bleeding compared to those who did not undergo these treatments. ## Data Availability All relevant data are within the manuscript and its Supporting Information files. ## Availability of Data and Materials All the data and materials used in this paper are available from the corresponding author upon reasonable request. ## Disclosure interest The authors declare that they have no conflicts of interest. ## Funding details The authors received no specific funding for this study. ## Acknowledgement The authors thank the School of Pharmacy, College of Health Sciences, Addis Ababa University, and the nursing staff at TASH and SPHMMC dialysis clinics, who were very cooperative and helpful in providing constant assistance. ## Footnotes * hanan.muzeyin{at}aau.edu.et * birhanabdella{at}gmail.com * addisumelkieejigu{at}gmail.com * tamrat.assefa{at}aau.edu.et * eskinder.ayalew{at}aau.edu.et ## Abbreviations AKI : Acute Kidney Injury HD : Hemodialysis SPHMMC : St. Paul’s Hospital Millennium Medical College TASH : Tikur Anbessa Specialized Hospital UFH : Unfractionated heparin. * Received February 28, 2024. * Revision received February 28, 2024. * Accepted February 29, 2024. * © 2024, Posted by Cold Spring Harbor Laboratory This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) ## References 1. 1.Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011;79(12):1361–9. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ki.2011.42&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21430640&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F29%2F2024.02.28.24303493.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000291093300012&link_type=ISI) 2. 2.Daugirdas JT, Blake PG, Ing TS. Handbook of dialysis: Fifth edition. Handbook of Dialysis: Fifth Edition. 2014. 1–900 p. 3. 3.Dirkes S, Wonnacott R. Continuous Renal Replacement Therapy and Anticoagulation: What Are the Options? Am Assoc Crit Nurses. 2016;36(2):1–12. 4. 4.Ross S. Anticoagulation in Intermittent Hemodialysis: Pathways, Protocols, and Pitfalls. Vet Clin North Am - Small Anim Pract. 2011;41(1):163–75. 5. 5.Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int. 2007;11(2):178–89. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1542-4758.2007.00166.x&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17403168&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F29%2F2024.02.28.24303493.atom) 6. 6. Mhatre V. Ho, Ji-Ann Lee and KCM. Use and Safety of Unfractionated Heparin for Anticoagulation During Maintenance Hemodialysis. Am J Kidney Dis. 2012;23(1):1– 7. 7. 7.Srisawat N, Lawsin L, Uchino S, Bellomo R, Kellum JA. Cost of acute renal replacement therapy in the intensive care unit: Results from The Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Study. Crit Care. 2010;14(2):1–10. [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F29%2F2024.02.28.24303493.atom) 8. 8.Kessler M, Moureau F, Nguyen P. Anticoagulation in Chronic Hemodialysis: Progress Toward an Optimal Approach. Semin Dial. 2015;28(5):474–89. [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F29%2F2024.02.28.24303493.atom) 9. 9.Cronin RE, Reilly RF. Unfractionated Heparin for Hemodialysis: Still the Best Option. Semin Dial. 2010;23(5):510–5. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1525-139X.2010.00770.x&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21039876&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F29%2F2024.02.28.24303493.atom) 10. 10.European Best Practice Guidelines Expert Group on Hemodialysis ERA. Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transpl. 2002;17:63–71. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ndt/17.suppl_7.63&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12386229&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F29%2F2024.02.28.24303493.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000178033400008&link_type=ISI) 11. 11.Royal Liverpool and Broadgreen University Hospitals NHS Trust. Protocol for anticoagulation of extracorporeal circuits during kidney replacement therapy or plasma exchange. 2015. 12. 12.Safadi S, Albright RC, Dillon JJ, Williams AW, Alahdab F, Brown JK, et al. Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice. Kidney Int Reports [Internet]. 2017;2(4):695–704. Available from: doi:10.1016/j.ekir.2017.03.003 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ekir.2017.03.003&link_type=DOI) 13. 13.Liang E. Outcomes Associated with a Heparin-Free Hemodialysis Protocol and Review of the Literature. J Clin Nephrol Ren Care. 2016;2(1):1–6. 14. 14.Muleta MB, Abebe E, Tadesse M, Berhae T, Muhammed M, Woodside K, et al. Original Article Milestones of Renal Replacement Therapy in Ethiopia. Ethiop Med J. 2020;Supplement(January):5–13. 15. 15.Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol. 2009;20(4):872–81. [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiam5lcGhyb2wiO3M6NToicmVzaWQiO3M6ODoiMjAvNC84NzIiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNC8wMi8yOS8yMDI0LjAyLjI4LjI0MzAzNDkzLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 16. 16.Krummel T, Scheidt E, Borni-duval C, Bazin D, Lefebvre F, Nguyen P, et al. Haemodialysis in patients treated with oral anticoagulant: should we heparinize? 2014;29(4):906–13. 17. 17.Herrero-Calvo JA, González-Parra E, Pérez-García R, Tornero-Molina F. Spanish study of anticoagulation in haemodialysis. Rev Nefrol. 2012;32(2):153–9. 18. 18.Shibiru T, Gudina EK, Habte B, Deribew A, Agonafer T. Survival patterns of patients on maintenance hemodialysis for end stage renal disease in Ethiopia: summary of 91 cases. BMC Nephrol. 2013;14(1–6). 19. 19.Albino BB, Balbi AL, Ponce D. Dialysis complications in AKI patients treated with extended daily dialysis: Is the duration of therapy important? Biomed Res Int. 2014;2014. 20. 20.François K, Wissing KM, Jacobs R, Boone D, Jacobs K, Tielemans C. Avoidance of systemic anticoagulation during intermittent haemodialysis with heparin-grafted polyacrilonitrile membrane and citrate-enriched dialysate: A retrospective cohort study. BMC Nephrol. 2014;15(1):1–7. 21. 21.Aleksandrova I V., Reǐ SI, Pervakova EI. Acute renal failure in critically ill patients. Anesteziol Reanimatol. 2007;294(4):72–6. 22. 22.Franchini M, Veneri D, Lippi G. Inflammation and hemostasis: A bidirectional interaction. Clin Lab. 2007;53(1–2):63–7. [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17323827&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F29%2F2024.02.28.24303493.atom) 23. 23.Sahota S, Rodby R. Inpatient hemodialysis without anticoagulation in adults. Clin Kidney J. 2014;7(6):1–5. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ckj/sft168&link_type=DOI) 24. 24.Murea M, Russell GB, Daeihagh P, Saran AM, Pandya K, Cabrera M, et al. Efficacy and safety of low-dose heparin in hemodialysis. Hemodial Int. 2018;22(1):74–81.